IP Library Patent Application 16543835
Patent Application
App. No. 16/543,835

ACECLIDINE ISOMERS AND SCALEMIC MIXTURES THEREOF FOR THE TREATMENT OF PRESBYOPIA

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/543,835
Abstract

The invention provides compositions containing aceclidine isomers and scalemic mixtures thereof for the treatment of presbyopia. The compositions optionally contain an alpha-adrenergic agonist, a cycloplegic agent, a cryoprotectant, a non-ionic surfactant and/or a viscosity enhancer.

Claims (20)

1 . A composition for the treatment of presbyopia comprising aceclidine wherein the S-enantiomer of aceclidine is greater than 50% by weight of the aceclidine.

2 . The composition of claim 1 , wherein the S-enantiomer is at least 60% by weight of the mixture.

3 . The composition of claim 1 , wherein the S-enantiomer is at least 70% by weight of the aceclidine.

4 . The composition of claim 1 , wherein the S-enantiomer is at least 80% by weight of the aceclidine.

5 . The composition of claim 1 , wherein the S-enantiomer is at least 90% by weight of the aceclidine.

6 . The composition of claim 1 , wherein the S-enantiomer is at least 99% by weight of the aceclidine.

7 . The composition of claim 1 , wherein the S-enantiomer is 100% by weight of the aceclidine.

8 . The composition of claim 1 , further comprising one or more agents selected from the group consisting of an alpha-adrenergic agonist, a cycloplegic agent, a cryoprotectant, a non-ionic surfactant and a viscosity agent.

9 . The composition of claim 1 , further comprising one or more preservatives.

10 . A method of treating presbyopia comprising administering the composition of claim 1 to a subject in need thereof.

11 . A composition for the treatment of presbyopia comprising aceclidine wherein the R-enantiomer of aceclidine is greater than 50% by weight of the aceclidine.

12 . The composition of claim 10 , wherein the R-enantiomer is at least 60% by weight of the mixture.

13 . The composition of claim 1 , wherein the R-enantiomer is at least 70% by weight of the aceclidine.

14 . The composition of claim 10 , wherein the R-enantiomer is at least 80% by weight of the aceclidine.

15 . The composition of claim 10 , wherein the R-enantiomer is at least 90% by weight of the aceclidine.

16 . The composition of claim 10 , wherein the R-enantiomer is at least 99% by weight of the aceclidine.

17 . The composition of claim 10 , wherein the R-enantiomer is 100% by weight of the aceclidine.

18 . The composition of claim 10 , further comprising one or more agents selected from the group consisting of an alpha-adrenergic agonist, a cycloplegic agent, a cryoprotectant, a non-ionic surfactant and a viscosity agent.

19 . The composition of claim 10 , further comprising one or more preservatives.

20 . A method of treating presbyopia comprising administering the composition of claim 10 to a subject in need thereof.

Assignments (4)
CHANGE OF NAME Recorded Apr 8, 2024
From: LENZ THERAPEUTICS, INC.
To: LENZ THERAPEUTICS OPERATIONS, INC.
Reel/Frame 067625/0816 →
CHANGE OF NAME Recorded Apr 3, 2024
From: PRESBYOPIA THERAPIES, INC.
To: LENZ THERAPEUTICS, INC.
Reel/Frame 067002/0157 →
CHANGE OF NAME Recorded Nov 9, 2020
From: PRESBYOPIA THERAPIES, LLC
To: PRESBYOPIA THERAPIES, INC.
Reel/Frame 054363/0516 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2020
From: HORN, GERALD
To: PRESBYOPIA THERAPIES, LLC
Reel/Frame 052042/0121 →